[Retracted] MicroRNA­155 enhances the activation of Wnt/ß­catenin signaling in colorectal carcinoma by suppressing HMG­box transcription factor 1.

Following the publication of this paper, it was drawn to the Editors' attention by a concerned reader that certain of the western blot assay data shown in Figs. 1C and 6A were strikingly similar to data appearing in different form in another article written by different authors. Owing to the fact that the contentious data in the above article were already under consideration for publication prior to its submission to Molecular Medicine Reports, the Editor has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a satisfactory reply. The Editor apologizes to the readership for any inconvenience caused. [the original article was published in Molecular Medicine Reports 13: 2221­2228, 2016; DOI: 10.3892/mmr.2016.4788].

MicroRNA-155 enhances the activation of Wnt/ß-catenin signaling in colorectal carcinoma by suppressing HMG-box transcription factor 1.

Colorectal carcinoma (CRC) is a malignant solid tumor arising from the large intestine and is associated with an increasing incidence and poor prognosis. Further understanding of the molecular mechanisms underlying CRC may contribute to the development of novel effective therapeutic strategies. MicroRNAs (miRs), including miR­155, have been reported to be associated with the etiology and biology of CRC; however, the molecular mechanisms by which miR­155 affect CRC remain to be fully elucidated. The present study used a multidisciplinary approach, involving reverse transcription­quantitative polymerase chain reaction, northern blotting, MTT assay, cell cycle progression analysis, immunoblotting, and animal experiments, to determine the possible targets of miR­155 in CRC cells. miR­155 was found to be overexpressed in CRC tissue samples, compared with paired normal colon tissue samples. In addition, the inhibition of miR­155 induced a deceleration in CRC cell proliferation and inactivation of the Wnt/ß­catenin signaling pathway. miR­155 suppression also reduced the growth of CRC xenografts in an animal model. HMG­box transcription factor 1 (HBP1) was identified as a novel target of miR­155, which mediated its effect on CRC via the Wnt/ß­catenin pathway. Furthermore, patients with CRC exhibiting higher serum levels of miR­155 exhibited reduced survival rates. In conclusion, the present study demonstrated that miR­155 may contribute to the progression and growth of CRC by enhancing the Wnt/ß­catenin pathway in an HBP1­associated mechanism. Therefore, miR­155 may be considered a promising therapeutic target for the treatment of CRC.

Dosage effect of rocuronium on intraoperative neuromonitoring in patients undergoing thyroid surgery.

The effect of different concentrations of rocuronium bromide used for anesthesia induction during thyroid surgery on the intraoperative recurrent laryngeal nerve monitoring was evaluated. One hundred patients undergoing thyroid operation were randomized into five groups (20 patients per group). Patients in group I were operated and monitored without the use of rocuronium bromide. Patients in groups II-V were respectively injected with 0.5x, 1x, 1.5x, and 2x ED95 rocuronium bromide intravenously. The time from injecting the rocuronium bromide to the beginning of tube insertion was recorded, the conditions of tracheal intubation were evaluated, and the changes in blood pressure and pulse during the intubation process were monitored. Vagus nerve/recurrent laryngeal nerve evoked muscle potential was monitored using the NIM-Response3.0 nerve electromyography monitor. The amplitude of electromyography signal was recorded every 5 min during 30 min after successful tracheal intubation. The tracheal intubation success rate was 100% in all groups. Compared with group I, intubating condition scores (Cooper scores) in the patients of groups II-V were higher (P < 0.05). The stability of intraoperative neuromonitoring signal amplitude in groups I-III met the monitoring standards. The findings suggest that the use of 0.5x or 1x ED95 rocuronium bromide during the anesthesia induction can improve the tracheal tube conditions without affecting the intraoperative recurrent laryngeal nerve monitoring. The use of 1x ED95 rocuronium bromide induction was associated with the best results.